Advanced Oncotherapy – CEO, CFO & Non-Exec director purchase shares in the company

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company at 9 pence per Ordinary Share on that […]

Advanced Oncotherapy – Director Dealing

Advanced Oncotherapy announces that Michael Sinclair, Executive Chairman of the Company, had yesterday purchased an option over 30 million ordinary shares of 1 penny each in the Company from Brahma AG at a cost of £300,000. The Option vests immediately, expires two years from today’s date and has an exercise price of 10p per Ordinary Share. […]

Advanced Oncotherapy (AVO) – Final Results for the year ended 31 December 2014

Advanced Oncotherapy (AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2014, a year of significant progress in the development of the Company’s LIGHT system. A number of key milestones in the development of the LIGHT system have also been completed following the […]

New survey shows 36-percent increase in pediatric patients treated with proton therapy

Most pediatric proton patients are younger than 10, with brain and spinal cord tumors Results from a new nationwide survey indicate a steady increase in the number of pediatric patients who are being treated with proton radiation therapy for cancerous and non-cancerous tumors. The research, led by Andrew L. Chang, M.D., medical director of pediatrics […]

Advanced Oncotherapy – Notice of Results

Advanced Oncotherapy (AVO) will announce its results for the year ended 31 December 2014 on Wednesday 3 June 2015.   A briefing for analysts will take place on the day.If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com. www.avoplc.com […]

Advanced Oncotherapy (AVO) announces successful RF Power testing of the first CCL unit

Advanced Oncotherapy (AVO) announces that the Radio Frequency Power tests of the first Coupled Cavity Linac unit have been successfully completed at the Company’s testing facility at CERN in line with expectations. The RF Power units, created by ScandiNova Systems AB, generate the high-power needed to accelerate protons to speeds whereby they can effectively target […]

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares and Warrants

Exercise of Warrants Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for treating cancer, announces that it has today issued 5,000,000 new ordinary shares at a subscription price of 1 penny each pursuant to the exercise of warrants. Issue of Further Shares and Warrants In accordance with the Supplemental Agreement with Brahma AG […]

Health Service Procurement Is a Mess – the Military Has Answers – Huffington Post

Health Service Procurement Is a Mess – the Military Has Answers – Huffington Post Sanjeev Pandya Chief Executive of Advanced Oncotherapy Despite reform, the NHS’ procurement process still delivers poor value for money, stifles medical innovation and prevents new entrants to the market. It’s time to look to the military for solutions. In 2002, the […]